相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiotoxic effects of angiogenesis inhibitors
Stephen J. H. Dobbin et al.
CLINICAL SCIENCE (2021)
Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials
Wanting Hou et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2021)
A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model
Jia-Qi Wu et al.
LIFE SCIENCES (2020)
Vascular toxicity associated with anti-angiogenic drugs
Karla B. Neves et al.
CLINICAL SCIENCE (2020)
Cabozantinib, a Multityrosine Kinase Inhibitor of MET and VEGF Receptors Which Suppresses Mouse Laser-Induced Choroidal Neovascularization
Xiaoli Zhang et al.
JOURNAL OF OPHTHALMOLOGY (2020)
Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity
Huda K. Mahmoud et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy
Shuang Qin et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Identification of Novel Anti-Liver Cancer Small Molecules with Better Therapeutic Index Than Sorafenib via Zebrafish Drug Screening Platform
Han-Syuan Lin et al.
CANCERS (2019)
Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies
Anand P. Singh et al.
CARDIOVASCULAR RESEARCH (2019)
Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model
Chiara Gabellini et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Efficacy of Lenvatinib, a multitargeted tyrosine kinase inhibitor, on laser induced CNV mouse model of neovascular AMD
Xian Wei et al.
EXPERIMENTAL EYE RESEARCH (2018)
Anti-angiogenic activity of para-coumaric acid methyl ester on HUVECs in vitro and zebrafish in vivo
He-Zhong Zhang et al.
PHYTOMEDICINE (2018)
Efficacy Comparison of Intravitreal Anti-VEGF Therapy for Three Subtypes of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
Jianqing Li et al.
JOURNAL OF OPHTHALMOLOGY (2018)
Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization
H. Guo et al.
ONCOGENE (2017)
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Arun Sharma et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases
Sara Rezzola et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2016)
Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models
Anand Giddabasappa et al.
EXPERIMENTAL EYE RESEARCH (2016)
Ten years of anti-vascular endothelial growth factor therapy
Napoleone Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Andrographolide inhibits tumor angiogenesis via blocking VEGFA/VEGFR2-MAPKs signaling cascade
Kaikai Shen et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2014)
Receptor Tyrosine Kinase-Mediated Angiogenesis
Michael Jeltsch et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
Vascular Development in the Zebrafish
Aniket V. Gore et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Anti-VEGF Treatment Strategies for Wet AMD
Jaclyn L. Kovach et al.
JOURNAL OF OPHTHALMOLOGY (2012)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?
Kristy J. Gotink et al.
ANGIOGENESIS (2010)
Platelet-Derived Growth Factor Receptor β Is Critical for Zebrafish Intersegmental Vessel Formation
Katie M. Wiens et al.
PLOS ONE (2010)
The role of the Angiopoietins in vascular morphogenesis
Markus Thomas et al.
ANGIOGENESIS (2009)
Synthesis and biological evaluation of pyrrolopyridazine derivatives as novel HER-2 tyrosine kinase inhibitors
Tang Peng Cho et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Small molecule screen for compounds that affect vascular development in the zebrafish retina
Satish S. Kitambi et al.
MECHANISMS OF DEVELOPMENT (2009)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
FoxH1 negatively modulates flk1 gene expression and vascular formation in zebrafish
Jayoung Choi et al.
DEVELOPMENTAL BIOLOGY (2007)
The role of VEGF and EGFR inhibition: Implications for combining anti-VEGF and anti-EGFR agents
Josep Tabernero
MOLECULAR CANCER RESEARCH (2007)
The regulation of vascular endothelial growth factors (VEGF-A -C, and -D) expression in the retinal pigment epithelium
Yasuhiro Ikeda et al.
EXPERIMENTAL EYE RESEARCH (2006)
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts
Anthony Polverino et al.
CANCER RESEARCH (2006)
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
FJ Giles et al.
LEUKEMIA RESEARCH (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Retinal angiogenesis in development and disease
RF Gariano et al.
NATURE (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Inhibition of zebrafish epidermal growth factor receptor activity results in cardiovascular defects
K Goishi et al.
MECHANISMS OF DEVELOPMENT (2003)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development
D Liang et al.
MECHANISMS OF DEVELOPMENT (2001)
Discovery of a novel Raf kinase inhibitor
JF Lyons et al.
ENDOCRINE-RELATED CANCER (2001)
Angiogenesis in cancer and other diseases
P Carmeliet et al.
NATURE (2000)
Kinase inhibitors in cancer therapy - A look ahead
HH Sedlacek
DRUGS (2000)
分享论文
